Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Meydan

Showing results (51-60 of 115) with videos related to

Pageof 12
Sort By:
Cancer Cell|February 3, 2023
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironmentJulie Leca, Franҫois Lemonnier, Cem Meydan, et al.
Cancer Research|October 17, 2020
Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug ResistanceShella Saint Fleur-Lominy, Nikki A Evensen, Teena Bhatla, et al.
Cell Reports|February 10, 2021
Clonal hematopoiesis before, during, and after human spaceflightNuria Mencia-Trinchant, Matthew J MacKay, Christopher Chin, et al.
Cell Reports|November 26, 2020
Clonal Hematopoiesis Before, During, and After Human SpaceflightNuria Mencia-Trinchant, Matthew J MacKay, Christopher Chin, et al.
Cancer Cell|May 13, 2020
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune ResponseWendy Béguelin, Matt Teater, Cem Meydan, et al.
Nature Immunology|January 12, 2021
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformationMartín A Rivas, Cem Meydan, Christopher R Chin, et al.
Cancer Cell|April 9, 2024
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesisDarko Barisic, Christopher R Chin, Cem Meydan, et al.
Cancer Cell|December 6, 2024
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionYusuke Isshiki, Xi Chen, Matt Teater, et al.
Blood Advances|October 2, 2023
Resistance to PRMT5-targeted therapy in mantle cell lymphomaMackenzie Elizabeth Long, Shirsha Koirala, Shelby Sloan, et al.
Cancer Discovery|April 15, 2017
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic ModifiersJacob L Glass, Duane Hassane, Bas J Wouters, et al.
Pageof 12

Showing results (51-60 of 115) with videos related to

Sort By:
Pageof 12
Cancer Cell|February 3, 2023
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironmentJulie Leca, Franҫois Lemonnier, Cem Meydan, et al.
Cancer Research|October 17, 2020
Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug ResistanceShella Saint Fleur-Lominy, Nikki A Evensen, Teena Bhatla, et al.
Cell Reports|February 10, 2021
Clonal hematopoiesis before, during, and after human spaceflightNuria Mencia-Trinchant, Matthew J MacKay, Christopher Chin, et al.
Cell Reports|November 26, 2020
Clonal Hematopoiesis Before, During, and After Human SpaceflightNuria Mencia-Trinchant, Matthew J MacKay, Christopher Chin, et al.
Cancer Cell|May 13, 2020
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune ResponseWendy Béguelin, Matt Teater, Cem Meydan, et al.
Nature Immunology|January 12, 2021
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformationMartín A Rivas, Cem Meydan, Christopher R Chin, et al.
Cancer Cell|April 9, 2024
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesisDarko Barisic, Christopher R Chin, Cem Meydan, et al.
Cancer Cell|December 6, 2024
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionYusuke Isshiki, Xi Chen, Matt Teater, et al.
Blood Advances|October 2, 2023
Resistance to PRMT5-targeted therapy in mantle cell lymphomaMackenzie Elizabeth Long, Shirsha Koirala, Shelby Sloan, et al.
Cancer Discovery|April 15, 2017
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic ModifiersJacob L Glass, Duane Hassane, Bas J Wouters, et al.
Pageof 12